Get the Stockscreener App
4.48
4.67%
0.20
Tharimmune Inc stock is traded at $4.48, with a volume of 469.22K.
It is up +4.67% in the last 24 hours and up +55.02% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$4.28
Open:
$4.21
24h Volume:
469.22K
Relative Volume:
0.58
Market Cap:
$177.09M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.3525
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+8.21%
1M Performance:
+55.02%
6M Performance:
+239.39%
1Y Performance:
+135.79%
1-Day Range:
$4.21
$4.645
1-Week Range:
$3.82
$4.83
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
4.48 | 169.19M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Tharimmune Inc Stock (THAR) Latest News
Is Tharimmune Inc. a potential multi baggerQuarterly Portfolio Summary & Long-Term Growth Plans - mfd.ru
Pharma News: Is VNOM a good stock for dollar cost averagingPortfolio Gains Summary & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Investment Report: Is Tharimmune Inc a potential multi baggerJuly 2025 Snapshot & Entry Point Confirmation Signals - baoquankhu1.vn
Will Tharimmune Inc. benefit from geopolitical trendsDividend Hike & Low Drawdown Investment Ideas - mfd.ru
Does Tharimmune Inc. have strong EBITDA marginsJuly 2025 Momentum & Stepwise Entry and Exit Trade Signals - mfd.ru
Is Tharimmune Inc. stock showing strong momentumJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - mfd.ru
Tharimmune appoints new chairman and COO to advance digital asset strategy - Investing.com Canada
Tharimmune Elects CEO Mark Wendland as Chair, Names Angela Radkowski as COO - marketscreener.com
Tharimmune strengthens leadership and governance for Canton strategy - TipRanks
Tharimmune appoints new chairman and COO to advance digital asset strategy By Investing.com - Investing.com South Africa
Ex-DRW and Citadel exec tapped to run Tharimmune's Canton push - Stock Titan
Is Tharimmune Inc a cyclical or defensive stockPortfolio Growth Summary & Community Verified Watchlist Alerts - baoquankhu1.vn
Tharimmune Closes $545M Private Placement for Blockchain Strategy - MSN
Winners Losers: Does Tharimmune Inc offer margin of safetyJuly 2025 EndofMonth & Capital Efficient Trade Techniques - baoquankhu1.vn
Aug Fed Impact: What are analysts price targets for Affinity Bancshares IncStop Loss & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Tharimmune adds former CFTC commissioner and DRW executive to board By Investing.com - Investing.com Nigeria
Tharimmune Adds Jill Sommers And William Wiley To Board As Canton Network Strategy Expands - Pulse 2.0
Risk Off: Is Tharimmune Inc a cyclical or defensive stockJuly 2025 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Tharimmune Appoints Jill Sommers and William Wiley To Board - citybiz
Tharimmune Adds New Directors to Support Digital Strategy - TipRanks
Tharimmune adds former CFTC commissioner and DRW executive to board - Investing.com
Ex-CFTC regulator joins Tharimmune board amid blockchain finance shift - stocktitan.net
Loss Report: Is Tharimmune Inc a cyclical or defensive stockGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost - MarketBeat
THAR: All proposals, including director elections and share issuances, were approved by shareholders - TradingView
Tharimmune Gains Approval To Run Super Validator On Canton Network - RTTNews
Why is Tharimmune Inc. stock going up2025 Winners & Losers & Community Verified Trade Alerts - mfd.ru
The Canton Network, Its Coin, And Where It Might Be In 8 Years (Cryptocurrency: CC-USD) - Seeking Alpha
Tharimmune approved as super validator on Canton Network By Investing.com - Investing.com South Africa
Tharimmune Announces Expanded Role as Super Validator on Canton Network - MEXC
Weekly Earnings: Is TORM plc stock a falling knife or bargain buyJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Tharimmune Approved as Super Validator on Canton Network - TipRanks
Tharimmune approved as super validator on Canton Network - Investing.com
Tharimmune, Inc. Announces Role as Super Validator on Canton Network - TradingView
Tharimmune Advances Digital Asset Strategy via Canton Network - Intellectia AI
Tharimmune, Inc. Announces Expanded Role as Super Validator on Canton Network - marketscreener.com
Aug Retail: Will Tharimmune Inc benefit from geopolitical trendsEarnings Overview Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Tharimmune closes $55 million registered direct offering By Investing.com - Investing.com Australia
Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization - Seeking Alpha
Tharimmune, Inc. announces closing of $55 million underwritten registered direct offering - marketscreener.com
Tharimmune, Inc. Announces Closing Of $55 Million Underwritten Registered Direct Offering - TradingView
Tharimmune Completes $55 Million Registered Direct Offering - TipRanks
Tharimmune closes $55 million registered direct offering - Investing.com
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering - marketscreener.com
Tharimmune Signs Underwriting Agreement With Clear Street - TradingView
Biotech and blockchain player Tharimmune raises $55M for Canton strategy - Stock Titan
Tharimmune prices $55M registered offering - MSN
Canton Network Price Prediction 2026: Why is $CC Surging - Coin Gabbar
Tharimmune prices $55 million registered offering to fund digital strategy By Investing.com - Investing.com India
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tharimmune Inc Stock (THAR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parikh Sanam | Director |
Jun 20 '25 |
Buy |
1.45 |
1,000 |
1,450 |
1,770 |
| Appajosyula Sireesh | Chief Executive Officer |
Jun 20 '25 |
Buy |
1.48 |
61,496 |
90,973 |
64,868 |
| Parikh Sanam | Director |
May 15 '25 |
Buy |
1.30 |
770 |
1,001 |
770 |
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):